Allogene Therapeutics, Inc. (ALLO) analyst actions
Rating and price-target actions on ALLO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ALLO overview →
1 measured ALLO analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse | Press release | -0.89% | +7.96% |
Keep exploring
More ALLO: earnings → · SEC filings → · ALLO overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MATEON THERAPEUTICS (MATN) | 318 | 0.00% | 35% |
| Senseonics Holdings, Inc. (SENS) | 318 | -0.44% | 42% |
| Denali Therapeutics Inc. (DNLI) | 316 | +0.07% | 51% |
| Myomo Inc. (MYO) | 315 | +0.35% | 54% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.